Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid leukemia (AML). Howev...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Schmalbrock, Laura K., Dolnik, Anna, Cocciardi, Sibylle, Sträng, Eric, Theis, Frauke, Jahn, Nikolaus, Panina, Ekaterina, Blätte, Tamara J., Herzig, Julia, Skambraks, Sabrina, Rücker, Frank G., Gaidzik, Verena I., Paschka, Peter, Fiedler, Walter, Salih, Helmut R., Wulf, Gerald, Schroeder, Thomas, Lübbert, Michael, Schlenk, Richard F., Thol, Felicitas, Heuser, Michael, Larson, Richard A., Ganser, Arnold, Stunnenberg, Hendrik G., Minucci, Saverio, Stone, Richard M., Bloomfield, Clara D., Döhner, Hartmut, Döhner, Konstanze, Bullinger, Lars
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2021
Pynciau:
Myeloid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8233666/
https://ncbi.nlm.nih.gov/pubmed/33598693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007626
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg